These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24962792)

  • 1. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
    Ardini E; Bosotti R; Borgia AL; De Ponti C; Somaschini A; Cammarota R; Amboldi N; Raddrizzani L; Milani A; Magnaghi P; Ballinari D; Casero D; Gasparri F; Banfi P; Avanzi N; Saccardo MB; Alzani R; Bandiera T; Felder E; Donati D; Pesenti E; Sartore-Bianchi A; Gambacorta M; Pierotti MA; Siena S; Veronese S; Galvani A; Isacchi A
    Mol Oncol; 2014 Dec; 8(8):1495-507. PubMed ID: 24962792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
    Lee SJ; Li GG; Kim ST; Hong ME; Jang J; Yoon N; Ahn SM; Murphy D; Christiansen J; Wei G; Hornby Z; Lee DW; Park JO; Park YS; Lim HY; Hong SN; Kim SH; Kang WK; Park K; Park WY; Kim KM; Lee J
    Oncotarget; 2015 Nov; 6(36):39028-35. PubMed ID: 26472021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.
    Park DY; Choi C; Shin E; Lee JH; Kwon CH; Jo HJ; Kim HR; Kim HS; Oh N; Lee JS; Park OK; Park E; Park J; Shin JY; Kim JI; Seo JS; Park HD; Park J
    Oncotarget; 2016 Feb; 7(7):8399-412. PubMed ID: 26716414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma.
    Créancier L; Vandenberghe I; Gomes B; Dejean C; Blanchet JC; Meilleroux J; Guimbaud R; Selves J; Kruczynski A
    Cancer Lett; 2015 Aug; 365(1):107-11. PubMed ID: 26001971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel in-cell ELISA method for screening of compounds inhibiting TRKA phosphorylation, using KM12 cell line harboring TRKA rearrangement.
    Pandre MK; Shaik S; Satya Pratap VVV; Yadlapalli P; Yanamandra M; Mitra S
    Anal Biochem; 2018 Mar; 545():78-83. PubMed ID: 29360440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451
    Tatematsu T; Sasaki H; Shimizu S; Okuda K; Shitara M; Hikosaka Y; Moriyama S; Yano M; Brown J; Fujii Y
    Mol Clin Oncol; 2014 Sep; 2(5):725-730. PubMed ID: 25054037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
    Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
    Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
    [No Abstract]   [Full Text] [Related]  

  • 8. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
    Sartore-Bianchi A; Ardini E; Bosotti R; Amatu A; Valtorta E; Somaschini A; Raddrizzani L; Palmeri L; Banfi P; Bonazzina E; Misale S; Marrapese G; Leone A; Alzani R; Luo D; Hornby Z; Lim J; Veronese S; Vanzulli A; Bardelli A; Martignoni M; Davite C; Galvani A; Isacchi A; Siena S
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway.
    Kato Y; Matsumoto M; Takano N; Hirao M; Matsuda K; Tozuka T; Onda N; Nakamichi S; Takeuchi S; Miyanaga A; Noro R; Gemma A; Seike M
    Cancer Med; 2024 Jun; 13(12):e7393. PubMed ID: 38923428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders.
    Chen L; Chen Y; Zhang C; Jiao B; Liang S; Tan Q; Chai H; Yu W; Qian Y; Yang H; Yao W; Yu J; Luo Y; Plewe M; Wang J; Han XR; Liu J
    J Med Chem; 2020 Dec; 63(23):14562-14575. PubMed ID: 33058680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas.
    Butti MG; Bongarzone I; Ferraresi G; Mondellini P; Borrello MG; Pierotti MA
    Genomics; 1995 Jul; 28(1):15-24. PubMed ID: 7590742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
    Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
    Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
    Vaishnavi A; Capelletti M; Le AT; Kako S; Butaney M; Ercan D; Mahale S; Davies KD; Aisner DL; Pilling AB; Berge EM; Kim J; Sasaki H; Park S; Kryukov G; Garraway LA; Hammerman PS; Haas J; Andrews SW; Lipson D; Stephens PJ; Miller VA; Varella-Garcia M; Jänne PA; Doebele RC
    Nat Med; 2013 Nov; 19(11):1469-1472. PubMed ID: 24162815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRKA expression and
    Mauri G; Valtorta E; Cerea G; Amatu A; Schirru M; Marrapese G; Fiorillo V; Recchimuzzo P; Cavenago IS; Bonazzina EF; Motta V; Lauricella C; Veronese S; Tosi F; Maiolani M; Rospo G; Truini M; Bonoldi E; Christiansen J; Potts SJ; Siena S; Sartore-Bianchi A
    J Clin Pathol; 2018 Oct; 71(10):926-931. PubMed ID: 29802225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain.
    Greco A; Mariani C; Miranda C; Lupas A; Pagliardini S; Pomati M; Pierotti MA
    Mol Cell Biol; 1995 Nov; 15(11):6118-27. PubMed ID: 7565764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-Pharmacodynamic-Efficacy Modeling of ONO-7579, a Novel Pan-Tropomyosin Receptor Kinase Inhibitor, in a Murine Xenograft Tumor Model.
    Iida H; Fujikawa R; Kozaki R; Harada R; Hosokawa Y; Ogawara KI; Ohno T
    J Pharmacol Exp Ther; 2020 Jun; 373(3):361-369. PubMed ID: 32217770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Foretinib Overcomes Entrectinib Resistance Associated with the
    Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
    Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification and characterization of a novel
    Milione M; Ardini E; Christiansen J; Valtorta E; Veronese S; Bosotti R; Pellegrinelli A; Testi A; Pietrantonio F; Fucà G; Wei G; Murphy D; Siena S; Isacchi A; De Braud F
    Oncotarget; 2017 Aug; 8(33):55353-55360. PubMed ID: 28903424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assignment of the human a-tropomyosin gene TPM3 to 1q22-->q23 by fluorescence in situ hybridisation.
    Wilton SD; Eyre H; Akkari PA; Watkins HC; MacRae C; Laing NG; Callen DC
    Cytogenet Cell Genet; 1995; 68(1-2):122-4. PubMed ID: 7956350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs.
    Kita K; Arai S; Nishiyama A; Taniguchi H; Fukuda K; Wang R; Yamada T; Takeuchi S; Tange S; Tajima A; Nakada M; Yasumoto K; Motoo Y; Murakami T; Yano S
    Cancer Med; 2017 Dec; 6(12):2972-2983. PubMed ID: 29125233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.